- Home
- QURE vs LNSR Comparison
QURE vs LNSR Comparison
Compare QURE & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | LNSR |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 142.0M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | QURE | LNSR |
|---|---|---|
| Price | $23.87 | $11.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 1 |
| Target Price | ★ $58.55 | $15.00 |
| AVG Volume (30 Days) | ★ 2.9M | 48.6K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,751,000.00 | ★ $59,141,000.00 |
| Revenue This Year | N/A | $19.55 |
| Revenue Next Year | $153.45 | $35.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.02 |
| 52 Week Low | $7.76 | $7.25 |
| 52 Week High | $71.50 | $17.31 |
Technical Indicators
Market Signals| Indicator | QURE | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 52.91 |
| Support Level | $19.29 | $11.77 |
| Resistance Level | $25.69 | $12.19 |
| Average True Range (ATR) | 1.48 | 0.30 |
| MACD | 0.88 | -0.02 |
| Stochastic Oscillator | 70.90 | 27.16 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.